Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?

Hubert Kolb; Matthias von Herrath

doi:10.1016/j.cmet.2016.10.009

Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?

Cell Metab. 2017 Feb 7;25(2):233-241. doi: 10.1016/j.cmet.2016.10.009. Epub 2016 Nov 10.

Authors

Hubert Kolb¹, Matthias von Herrath²

Affiliations

¹ West-German Centre of Diabetes and Health, Düsseldorf Catholic Hospital Group, Hohensandweg 37, 40591 Düsseldorf, Germany; Faculty of Medicine, University of Düsseldorf, 40225 Düsseldorf, Germany. Electronic address: hubert.kolb@uni-duesseldorf.de.
² Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92014, USA; Novo Nordisk Diabetes Research and Development Center, Seattle, WA 98191, USA. Electronic address: matthias@lji.org.

PMID: 27839907
DOI: 10.1016/j.cmet.2016.10.009

Abstract

T cell-directed immunosuppression only transiently delays the loss of β cell function in recent-onset type 1 diabetes. We argue here that the underlying disease process is carried by innate immune reactivity. Inducing a non-polarized functional state of local innate immunity will support regulatory T cell development and β cell proliferation.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Autoimmunity
Diabetes Mellitus, Type 1 / diagnosis
Diabetes Mellitus, Type 1 / immunology*
Diabetes Mellitus, Type 1 / therapy*
Disease Models, Animal
Humans
Immunotherapy*
Insulin-Secreting Cells / metabolism
Insulin-Secreting Cells / pathology
Treatment Outcome